Anzeige
Mehr »
Montag, 01.09.2025 - Börsentäglich über 12.000 News
Blockbuster-Potenzial und Übernahmefantasie: Hier entsteht das nächste Big Pharma-Ziel!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4142W | ISIN: US4268974015 | Ticker-Symbol: 3360
Berlin
05.06.23 | 13:22
9,162 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
HEPION PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
HEPION PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur HEPION PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.08.Hepion Pharmaceuticals, Inc. - 10-Q, Quarterly Report2
22.07.NSE - Hepion Pharmaceuticals, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities6
30.06.Finanzvorstand John Brancaccio verlässt Hepion Pharmaceuticals zum Wochenbeginn6
30.06.Hepion Pharmaceuticals, Inc. - 8-K, Current Report1
25.06.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Successfully Completes Application to the OTCQB283MORRISTOWN, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTCQB:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for...
► Artikel lesen
HEPION PHARMACEUTICALS Aktie jetzt für 0€ handeln
16.06.Hepion Pharmaceuticals appoints Kaouthar Lbiati as interim CEO3
16.06.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer391MORRISTOWN, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (OTC:HEPA), a clinical stage biopharmaceutical company that is developing and commercializing diagnostic tests for...
► Artikel lesen
09.06.Hepion Pharmaceuticals, Inc. - 8-K, Current Report2
30.05.Hepion Pharmaceuticals, Inc. - 8-K, Current Report7
19.05.Hepion Pharmaceuticals, Inc. - 10-Q, Quarterly Report3
12.05.Hepion Pharmaceuticals to be delisted from Nasdaq4
12.05.Hepion Pharmaceuticals wird von der Nasdaq gestrichen9
12.05.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq497MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis...
► Artikel lesen
07.05.Hepion Pharmaceuticals schließt Lizenzvertrag für Diagnosetests ab2
07.05.Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC177 MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis...
► Artikel lesen
06.05.Hepion Pharmaceuticals, Inc. - 8-K, Current Report2
17.04.Hepion Pharmaceuticals, Inc. - 8-K, Current Report1
08.04.Hepion Pharmaceuticals, Inc. - 10-K, Annual Report20
19.03.Hepion Pharmaceuticals, Inc. - 8-K, Current Report3
14.03.Hepion Pharmaceuticals Announces 1-for-50 Reverse Stock Split To Maintain Nasdaq Listing9
Weiter >>
26 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2